Oxford Biomedica (LSE:OXB) has set itself an ambitious goal: around £500 million of annual Revenue by 2030, more than double the top of its 2026 guidance. Its interim results in September offered fresh evidence on whether the client base is growing fast enough to support that aim. The question is how the company plans to get there, and what stands in the way.
A viral vector manufacturer
Oxford Biomedica is a contract development and Manufacturing organisation, or CDMO, specialising in viral vectors used in cell and gene therapies. Customers developing these treatments outsource process development and manufacturing to it. Headquartered in Oxford, the company has sites in Oxfordshire, Lyon and Strasbourg in France, and Bedford, Massachusetts and Durham, North Carolina in the US. Dr Frank Mathias is chief executive, and the shares trade on the London Stock Exchange under the ticker OXB.
Interim results and client growth
On 22 September 2026, Oxford Biomedica reported revenue of £79.8 million for the six months to 30 June, up 9% on a reported basis and 10% at constant currency. The company said it had 50 clients covering 59 programmes, up from 37 clients and 44 programmes in September 2025, and signed 17 new clients in the half, more than 30% above the total for the whole of 2025.
The revenue Backlog stood at about £193 million at 30 June, and around £168 million of 2026 revenue was covered by client orders as of September. The company put its non-risk-adjusted pipeline at roughly $713 million, 30% higher year on year. It reiterated 2026 guidance of £180 million to £200 million revenue at constant currency and forecast revenue growth of 25% to 30% in 2027. Its medium-term targets are revenue of about £500 million by 2030 and EBITDA margins approaching 30% over the longer term.
Strategic progress highlighted in the report included GMP manufacturing becoming operational at Durham, with a first GMP run completed, a commercial Supply agreement with Bristol Myers Squibb for lentiviral vectors and a new AAV manufacturing agreement with Plowshare Therapies. Eric Schmidhäuser was appointed chief operating officer in August. Dave Backer was named head of the Durham site.
Profitability and cash
Growth has not yet translated into profit. Operating EBITDA was a loss of £7.8 million, or £2.5 million on an adjusted basis, improved from a £3.9 million loss a year earlier. The operating loss widened to £29.1 million from £23.6 million, and the loss after tax to £37.0 million from £26.9 million. Cash fell to £75.3 million at 30 June from £96.9 million at the end of 2025. After Debt of £53.8 million under its Oaktree facility, net cash was £21.4 million. For 2026, the company expects a mid-single-digit EBITDA Margin excluding one-off costs. On a reported basis, the company expects a low-single-digit margin.
Risks to the plan
The 2030 target depends on clients' therapies progressing through trials and, in some cases, to commercial launch, which is inherently uncertain in cell and gene therapy. Funding conditions for biotech customers can change quickly. Continued losses and a shrinking cash balance leave limited room for delays, and the debt Facility adds fixed obligations. Expanding US capacity carries execution and utilisation risk until new sites are well loaded. Recent purchases of shares by vice chair Peter Soelkner were small in size.
Conclusion
Oxford Biomedica is pursuing its £500 million revenue goal by rapidly widening its client and programme base, building order cover and adding US capacity, while relying on contracts such as the BMS supply deal. The interim figures show momentum in client wins and backlog, but losses and declining cash mean execution on margins will be central. Updates on order cover and 2027 contracts will indicate whether growth is holding.






Please wait processing your request...